ArticleMolecular diversity2026
Discovering anti-obesity blue food compounds via combined deep learning and in silico approaches.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blue foods, such as fish and aquatic sources, are rich in bioactive compounds with potential health benefits, including anti-obesity effects. AMPK, a key regulator of energy homeostasis and adipogenesis, plays a vital role in combating obesity by inhibiting adipocyte differentiation. This study aimed to identify natural AMPK activators from underexplored blue foods using a deep learning-based compound-protein interaction (CPI) prediction model that incorporates both local and global features of proteins and compounds. Local and global molecular characteristics were systematically represented using sequence-based encodings, molecular fingerprints, and protein descriptors to enhance the model’s ability to capture diverse biochemical relationships. The deep learning framework integrated these multimodal features through neural network modules to predict potential compound–protein interactions. In silico molecular docking was performed to refine the predicted interactions, leading to the identification of 94 top-scoring compounds with strong binding affinity toward AMPK. In vitro validation of five commercially available compounds confirmed anti-obesity activity. Notably, cyclo(Pro-Val) from Ulva pertusa, activated AMPK and modulated key adipogenic markers, suggesting its potential as a natural AMPK activator for obesity prevention and the feasibility of AI-driven screening for marine bioactives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.